First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar

Tyenne Version Is Approved In SC And IV Formulations; Rival Biogen Is Yet To Launch

 
• By Dave Wallace
  
Sprinters running off from starting blocks
Fresenius Kabi has been first to launch a US tocilizumab biosimilar • Source: Shutterstock

More from Products

More from Generics Bulletin